Table 2.
Effect of DAPA on plasma insulin, C-peptide, glucagon, epinephrine, and norepinephrine concentrations in subjects with diabetes (T2D) and without diabetes (non-DM)
| DAPA | Placebo | |||||
|---|---|---|---|---|---|---|
| Baseline | End | P value | Baseline | End | P value | |
| T2D | ||||||
| Insulin (μU/mL) | 14 ± 2.7 | 11 ± 1.9 | 0.024 | 12 ± 1.9 | 10 ± 1.4 | 0.047 |
| C-peptide (ng/mL) | 4.40 ± 0.47 | 3.67 ± 0.37 | 0.005 | 4.37 ± 0.52 | 3.71 ± 0.36 | 0.036 |
| Glucagon (pg/mL) | 45 ± 13 | 54 ± 14 | 0.095 | 42 ± 11 | 46 ± 11 | 0.456 |
| Epinephrine (pg/mL) | 6.8 ± 3.2 | 14 ± 6.1 | 0.389 | 4.8 ± 3.0 | 12 ± 4.8 | 0.071 |
| Norepinephrine (pg/mL) | 579 ± 156 | 712 ± 196 | 0.432 | 556 ± 169 | 639 ± 202 | 0.140 |
| Non-DM | ||||||
| Insulin (μU/mL) | 10 ± 2.0 | 7.5 ± 1.1 | 0.043 | 9.1 ± 1.8 | 8.2 ± 1.6 | 0.128 |
| C-peptide (ng/mL) | 3.4 ± 0.4 | 2.8 ± 0.3 | 0.006 | 3.5 ± 0.4 | 3.1 ± 0.4 | 0.008 |
| Glucagon (pg/mL) | 49 ± 6.3 | 49 ± 6.6 | 0.985 | 47 ± 4.4 | 43 ± 4.6 | 0.137 |
| Epinephrine (pg/mL) | 35 ± 8.5 | 44 ± 13 | 0.225 | 40 ± 10 | 44 ± 10 | 0.091 |
| Norepinephrine (pg/mL) | 482 ± 81 | 471 ± 105 | 0.793 | 517 ± 98 | 564 ± 123 | 0.403 |
Data are mean ± SEM.